Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
Annales Francaises D'Anesthesie Et De Reanimation|July 13, 2005
[Digestive surgery and varicose vein surgery]A Steib, S Laporte, B Vailly, et al.
Presse Medicale (Paris, France : 1983)|April 26, 2000
[Bepridil: importance of serum level in treatment surveillance]A Viallon, S Laporte-Simitsidis, V Pouzet, et al.
Annals of the New York Academy of Sciences|January 1, 1991
Circadian dynamics of coagulation and chronopathology of cardiovascular and cerebrovascular events. Future therapeutic implications for the treatment of these disorders?H Decousus, C Boissier, B Perpoint, et al.
Journal Des Maladies Vasculaires|June 17, 2014
Prospective multicentre observational study of lymphedema therapy: POLIT studyI Quéré, E Presles, M Coupé, et al.
Fundamental & Clinical Pharmacology|March 10, 2009
Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acidX Delavenne, S Laporte, S Demasles, et al.
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|May 1, 2013
[Value of polymerase chain reaction in serum for the diagnosis of enteroviral meningitis]S Marque Juillet, M Lion, B Pilmis, et al.
Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|November 11, 2011
[Laparoscopic colorectal resection for deep pelvic endometriosis: Evaluation of post-operative outcome]L Boileau, S Laporte, J-F Bourgaux, et al.
Chronobiology International|April 11, 2000
Establishing the dose-dependent daily variations of a low molecular weight heparin (Fraxiparine) through a population approach analysis in the ratD Abrial, A Blanc, M Réhailia, et al.
Haemostasis|March 17, 2001
A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in ratsD Abrial, A Blanc, M Réhailia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2018
Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events-a meta-analysisJ C Trone, E Ollier, C Chapelle, et al.
Pageof 10